Nearly two-thirds of Nephrologists Cite Limited Treatment Options as Alport Syndrome’s Greatest Challenge Amid Growing Pipeline Interest, According to Spherix Global Insights

Filspari and Vanrafia lead nephrologists’ most desired pipeline options as physicians seek therapies capable of improving renal outcomes beyond today’s supportive-care paradigm.

Exton, PA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Despite a wave of new therapies reshaping treatment across rare and glomerular kidney diseases, Alport syndrome has largely been left behind. Among kidney diseases evaluated by Spherix Global Insights, nephrologists now rank Alport syndrome as having the greatest unmet need.

New findings from Spherix Global Insights’ Market Dynamix™: Alport Syndrome (US) 2026 reveal that nearly two-thirds of nephrologists identify the lack of approved or adequate treatment options as the single greatest challenge in managing Alport syndrome.

The limitations of the current treatment paradigm are also evident in physicians’ assessments of their own patients. Despite widespread use of renin-angiotensin-aldosterone system inhibitors (RAASi) and increasing use of SGLT2 inhibitors, nephrologists estimate that just over half of their Alport syndrome patients are optimally managed.

Current treatment remains centered on renal protection with nearly all surveyed nephrologists initiating an ACE inhibitor or ARB as first-line therapy, while more than three-quarters say SGLT2 inhibitors are commonly added when patients do not respond adequately to optimized RAASi therapy.

At the same time, physicians place considerable importance on intervening before substantial kidney function is lost. More than nine in ten rate slowing eGFR decline and initiating nephroprotective therapy as early as possible as highly important treatment goals, underscoring the demand for therapies that can meaningfully alter the trajectory of renal decline.

Physicians Want Better Options — but Also Better Evidence

The emerging Alport syndrome pipeline is generating considerable interest, although nephrologists appear unwilling to equate novelty with meaningful clinical advancement.

When physicians evaluate future treatments, slowing chronic kidney disease(CKD) progression, reducing proteinuria and strong supporting clinical evidence rank above attributes such as dosing convenience, reduced monitoring burden and even an Alport-specific disease-modifying mechanism. Comparative effectiveness across emerging therapeutic approaches also stands out as the most important remaining evidence gap.

This high bar for evidence may become increasingly important as agents with mechanisms already familiar to nephrologists from their use in other glomerular diseases move toward potential use in Alport syndrome.

Filspari (sparsentan), from Travere Therapeutics, and Vanrafia (atrasentan), from Novartis, generate the greatest overall interest among the pipeline options evaluated. Filspari appears among the top three most desired therapies for more than three in five nephrologists, while Vanrafia is selected by roughly half. Familiarity may be helping drive enthusiasm for both agents: respondents citing previous clinical experience, familiarity with safety profiles and mechanism of action, and evidence from other glomerular diseases as reasons for favoring these therapies.

Vanrafia provides a particularly clear example of how nephrologists may envision incorporating a new Alport syndrome therapy into practice.

More than half of surveyed nephrologists report high interest in Vanrafia for Alport syndrome, and nearly seven in ten anticipate prescribing the therapy within six months of an FDA approval. Physicians also estimate that more than half of their current non-dialysis Alport syndrome patients could potentially be candidates, assuming appropriate coverage and access.

Importantly, anticipated use is not confined to patients with more advanced kidney disease. Nephrologists most often envision initiating Vanrafia in patients with Stage 1 through Stage 3a CKD, generally on background ACE inhibitor or ARB therapy and frequently an SGLT2 inhibitor.

The findings suggest that the opportunity for emerging Alport syndrome therapies may extend beyond simply adding another treatment option. Physicians are looking for therapies that can preserve renal function earlier in the disease course while providing sufficiently compelling clinical evidence to warrant a shift beyond the established supportive-care paradigm.

At the same time, nephrologists continue to express interest in approaches that more directly address Alport syndrome’s underlying biology. Qualitative research reveals a desire for treatments capable of addressing the underlying collagen defect itself and potentially affecting both renal and extrarenal manifestations of the disease.

Spherix is measuring physician feedback across a quickly advancing Alport syndrome pipeline, including atrasentan (Novartis), BAY-3401016 (Bayer), exaluren (Eloxx), setanaxib (Calliditas), sparsentan (Travere), and vonafexor (Enyo). The competitive landscape may be shaped by two parallel expectations: near-term demand for therapies that demonstrate meaningful improvements in renal outcomes, and a longer-term aspiration for disease-modifying approaches that target the underlying genetic basis of Alport syndrome. Findings are drawn from Spherix Global Insights’ Market Dynamix™: Alport Syndrome (US) 2026, based on a quantitative survey of 106 nephrologists fielded July 10–20, 2026. The research also included qualitative interviews with ten nephrologists conducted July 28–August 5, 2026.

About Market Dynamix ™

Market Dynamix™ is an independent, data-driven service focused on understanding the evolving dynamics of specialty markets poised for disruption. Leveraging quantitative and qualitative research, the service evaluates current treatment approaches, unmet needs, and likely impact of pipeline agents over a three-to-five-year horizon.

About Spherix Global Insights

Spherix Global Insights is a leading independent provider of market intelligence and advisory services for specialty pharmaceutical and biotech markets. By combining physician, patient, and payer perspectives into a single integrated view, Spherix helps brand teams, market access stakeholders, and investors understand how a specialty market actually behaves, not how any one stakeholder describes it. The firm operates eight dedicated therapeutic franchises – Central Nervous System, Dermatology, Gastroenterology, Hematology, Nephrology, Oncology, Ophthalmology, and Rheumatology – alongside a fully dedicated Market Access team. Each franchise is led by hyper-focused analysts and researchers who track these specialty areas full-time, drawing on independently curated communities of vetted practicing specialists, KOLs, patients recruited through treating physicians and advocacy partners, and medical and pharmacy directors at commercial and government payers. Spherix delivers quarterly trending, launch tracking, chart audits, KOL synthesis, patient experience research, and payer and market access intelligence that support confident, strategic decision-making across the pharma lifecycle. Trusted by 19 of the top 20 pharmaceutical and biotech organizations, Spherix has been a go-to resource for more than a decade for leading brands, market access stakeholders, industry media outlets, financial analysts, professional organizations, and patient advocacy groups seeking an unbiased, holistic view of specialty markets.

To learn more, visit spherixglobalinsights.com or connect on LinkedIn.

For more information on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com

NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insights’ analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.

Kari McCarthy, Nephrology Franchise Head
Spherix Global Insights
484-879-4284
kari.mccarthy@spherixglobalinsights.com